SumZero .com

SumZero .com


Recent articles

The Bearish Case for BioTime

A light R&D budget, a technology that may not be commercially viable, and a stock prone to promotion make one investor skeptical of BioTime's prospects.

The Case for Buying IMAX

The company's potential is being missed by the Wall Street analyst crowd.